Русский
Current clinical and pharmacoeconomic aspects of osteoarthritis therapy
DOI: https://dx.doi.org/10.18565/pharmateca.2025.6.88-96
Zyryanov S.K., Bondarev A.V.
Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow, Russia
Osteoarthritis is a disabling disease whose prevalence is constantly growing, resulting in an increasing economic burden on healthcare systems, including in Russia. The high cost of osteoarthritis therapy creates the preconditions for finding the most pharmacoeconomically optimal treatment options for this disease. This article analyzes existing clinical data on the efficacy and safety of the main osteoarthritis therapies, for which pharmacoeconomic studies have been conducted over the last ten years.
About the Autors
S.K. Zyryanov, Dr. Sci. (Med.), Professor, Head of the Department of General and Clinical Pharmacology, Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow, Russia; ORCID: https://orcid.org/0000-0002-6348-6867
Anatoly V. Bondarev, Postgraduate Student, Department of General and Clinical Pharmacology, Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow, Russia; 1142221175@rudn.ru, ORCID: https://orcid.org/0009-0009-5286-1463 (corresponding author)
Similar Articles
